| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8236084 | International Journal of Radiation Oncology*Biology*Physics | 2009 | 8 Pages |
Abstract
Radiation dose and use of chemotherapy are independent predictors of OS in Stage III NSCLC, and concurrent chemoradiation is associated with the best survival. There is no interaction between RT dose and chemotherapy.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Li M.D. Ph.D., Candace R. M.D., Lujun M.D. Ph.D., James M.D., Gregory P. M.D., Susan M.D. Ph.D., Kemp M.D., Dean M.D., Feng-Ming M.D. Ph.D.,